Foundation Item:Project
supported by Lubeck Medical University ,Germany Author Resume:XU Ya-ping (徐娅苹),E-mail:
xuyap@yahoo.com
References:
[1]Akiyama,T., Sudo, S., Ogawara,
H., Toyoshima, T. and Yamamoto, T., 1986. The product of the human c-erbB2
gene: A 185-kilodalton with tyrosine kinase activity. Science, 323:
1644-1646. [2]Bahar, R., Kunishi, M., Kayada, Y. and Yashigo, K., 1997.
CD44 variants 6 (CD44v6) expression as a progression marker benign,
premalignant and malignant oral epithelial tissues. Int J Oral Maxillofac,
26: 443-446. [3]Baybaud-Diogene, H., Tetu, B., Morency, R., Fortin, A.
and Monteil, R.A.,1996. P53 overexpression in Head and Neck Squamous Cell
Carcinoma: Review of the literature. Orol Oncol, Eur J Cancer, 32B:
143-149. [4]Brummer, O., Athar, S., Riethdorf, L., Loning, T. and
Herbst, H., 1999. Matrix-metalloproteinase 1, 2, and 3 and their tissue
inhibitors 1and 2 in benign and malignant breast lesions: an in situ
hybridization study. Virchows Arch, 435: 566-573. [5]Chomchai, J.S.,
Du, W., Sarkar, F.H., Li, Y.W., Jacobs, J.R., Ensley, J.E., Sakr,W. and
Yoo,G.H., 1999. Prognostic significance of p53 gene mutations in laryngeal
cancer. Laryngoscope, 109: 455-459. [6]Curran, S. and Murray, G.I.,
2000. Matrix metalloproteinases: molecular aspects of their roles in
tumour invasion and metastasis. Eur of Cancer, 36:
1621-1630. [7]Guthert,U., Hofmann, M., Rudy, W., Reber, S., Zoeller,
M., Haussmann, I., Matzku,S., Wenzel, A., Ponta, H. and Herrlich, P.,
1991. A new variant of glycoprotein CD44 confers metastastic potential to
rat carcinoma cells. Cell, 65: 13-24. [8]Hong, S.D., Hong, S.P., Lee,
J.I. and Lim, C.Y., 2000. Expression of matrix metalloproteinase-2, and -9
in oral squamous cell carcinomas with regard to the metastatic potential.
Oral Oncology, 36: 207-213. [9]Liotta, L.A., 1986. Tumor invasion and
metastases-role of the extracellular matrix: Rhoads Memorial Award
Lecture. Cancer Res., 46: 1-7. [10]Lupu, R., Cardillo, M., Harris, L.,
Hijazi, M. and Rosenberg, K., 1987. Human breast cancer: correlation of
relapse and survival with amplification of the HER2/neu oncogene. Science,
235: 177-182. [11]Merz, H., Malisius, R., Mannweiler, S., Zhou,R.,
Hartmenn, W., Orscheschek, K., Moubayed, P. and Feller, A.C., 1995.
Methods in laboratory investigation immunoMax: a maximized
immunohistochemical method for the retrieval and enhancement of hidden
antigens. Laboratory Investigation, 73: 149-156. [12]Miyajima, J.,
Nakano, R. and Morimatsu, M., 1995. Analysis of expression of matrix
metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by
in situ hybridization. Ann Oto Rhino Larygol, 104:
678-684. [14]Ornstein, D.L., Macnab, J. and Cohn, K.H., 1999. Evidence
for tumor host cooperation in regulating MMP-2 expression in human colon
cancer. Clin Exp Metastasis, 17: 205-212. [15]Ostwarld, J., Pracht, O.,
Rhode, E. and Kramp, B., 1997. Are the products of CD44 exons v5 and v6
markers for metastasis of laryngeal carcinomas? Laryngorhinootologie,
76:295-299. [16]Overall, C.M., 1994. Regulation of tissue inhibitor of
matrix metalloproteinase expression, Inhibition of matrix
metalloproteinases. Ann NY Acad Sci, 732: 51-67. [17]Parker, S.L.,
Tong, T., Bolden, S. and Wingo, P.A., 1997. Cancer statistic, CA Cancer. J
Clin, 47: 5-27. [18]Polette, M., Clavel, C., Birembaut, P. and De
Clerck,Y.A., 1996. Localization by in situ hybridization of mRNAs encoding
stromelysin 3, tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2
and head and neck carcinoma. Pathol Res Pract, 189: 1052-1057. [19]Ro,
J., EI-Naggar, A., Ro, J.Y., Blick, M., Frye, D., Fraschini, G., Fritsch,
H. and Hortobagyi, G., 1989. C-erbB-2 amplification in node-negative human
breast cancer. Cancer Res, 49: 6941-6944. [20]Tan, M., Yao, J. and Yu,
D.,1997. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis
potential in human breast cancer cells without increasing their
transformation abilities. Cancer Res, 57: 1199-1205. [21]Tantaway, A.,
Louins, L. and Hamza, M.,1999. Expression of c-erbB-2 oncoprotein in
cancer of the larynx in relation to invasion of the cartilagenous
framework and prognosis. Eur Arch Otorhinolaryngol, 256:
72-77. [22]Theillet, C., 1993. P53 genes and solid tumors. Bull Cancer,
80: 693-6. [23]Vermeulen, P.B., Roland, L., Mertens, V., Van Marck, E.,
De Bruijn, E.A., Van Oosterom, A.T. and Dirix, L.Y., 1996. Correlation of
intratumoral microvessel density and p53 protein overexpression in human
colorectal adenocarcinoma. Microvasc Res, 51: 164-174. [24]Weinstein,
G.S., Nuamah, I.F. and Tucker, J., 1996. Moutone K: Evaluation of HER2/neu
(c-erbB-2) oncogene expression in organ sections of supraglottic squamous
cell carcinoma. Ann Oto Rhinol Laryngol, 105: 275-279. [25]Xia, W.,
Lau, Y.K., Zhang, H.Z., Lin, A.R., Lin, L., Kiyokawa, N., Clayman, G.L.
and Katz, R.L., 1997. Strong correlation between c-erbB-2 overexpression
and overall survival of patients with oral squamous cell carcinoma. Clin
Cancer Res, 3: 3-9. [26]Yu, Q. and Stamenkovic, I., 1999. Localization
of matrix metalloproteinase 9 to the cell surface provides a mechanism for
CD44-mediated tumor invasion. Gene and Development,
13:35-38. [12]O-charoentat, P., Modjtahedi, H., Rhys-Evans, P., Court,
W.J., Box, G.M. and Eccless, A., 2000. Epidermal growth factor-like
ligands differentially up-regulate matrix metalloproteinase-9 in head and
neck squamous cell carcinoma. Cancer Res, 60:
1121-1128.
|
Manuscript
Received:2002 Aug. 30
Manuscript
Revised:2002 Dec. 12
Published:2003 Aug. 30 | |